Research and Markets – Global T-Cell Immunotherapy Pipeline Analysis 2016-2017: Novartis, Kite Pharma, Juno … – Yahoo Finance
|
Research and Markets – Global T-Cell Immunotherapy Pipeline Analysis 2016-2017: Novartis, Kite Pharma, Juno …
Yahoo Finance The T-cell immunotherapy pipeline is very strong with a total of 139 drug candidates. Pharma giant such as Novartis, Kite Pharmaceuticals, Juno Therapeutics, Inc. and Sorrent Therapeutics, Inc. are actively involved in development of these therapeutics. |
